CAR T-Cell Therapy for Leukemia and Lymphoma

"Affirmative. The clinicaltrials.gov website reveals that this trial, first posted on March 26th 2018, is actively searching for participants. 87 individuals must be recruited from a sole facility."

"That is accurate. According to clinicaltrials.gov, this medical research was initially listed on March 26th 2018 and the latest update was made on November 5th 2022. At the moment, 87 patients need to be recruited from a single site for this trial."

"This trial is enrolling individuals who are between 3 and 39 years old."

"Due to the limited amount of data related to this treatment, our team has assigned a score of 1 for CD19/CD22 CAR T-Cells in terms of safety. This is because it's currently at its first stage trial phase and there are only minimal studies that have assessed efficacy."

"As of present, 889 studies exploring CD19/CD22 CAR T-Cells are being conducted internationally. Of those trials, 161 have reached the Phase 3 stage. The majority of these clinical trials are located in Philadelphia, Pennsylvania but there are over 28 thousand sites conducting research with this treatment modality."

"CD19/CD22 CAR T-Cells is normally employed to treat multiple sclerosis, but it can be an effective treatment for various other illnesses including mixed-cell type lymphoma, leukemia, myelocytic, acute and retinoblastoma."

"This medical study is seeking out 87 individuals aged 3 to 39 with diffuse lymphoma. To be qualified, these patients must have evidence of disease through flow cytometry, immunohistochemistry or PCR analysis; CD19 expression on more than 15% malignant cells via histology or 90% by flow cytometry (the method will depend on tissue available); Karnofsky/Lansky score over 50%; leukocyte and platelet count exceeding 750/mcL* and 50,000 mcL*, respectively; a B cell ALL diagnosis that has been unresponsive to standard chemotherapy regimens plus salvage therapy for which there are no other cur"